Taysha Gene Therapies, Inc. | Business Contracts

Registration Rights Agreement, by and between the Company and Astellas, dated October 21, 2022 (Filed With SEC on October 31, 2022)

Option Agreement, by and between the Company and Astellas, dated October 21, 2022 (Filed With SEC on October 31, 2022)

Amendment No. 1 to Sales Agreement, dated March 30, 2022, by and among the Company, Goldman Sachs & Co. LLC, SVB Securities LLC and Wells Fargo Securities, LLC (Filed With SEC on March 31, 2022)

First Amendment to Lease Agreement, dated December 14, 2021, by and between Pegasus Park, LLC and the Company (Filed With SEC on March 31, 2022)

License Agreement, by and between the Company and Abeona Therapeutics Inc., dated as of October 29, 2020 (Filed With SEC on March 3, 2021)

Amended and Restated Executive Employment Agreement, effective as of September 24, 2020, by and between the Company and RA Session II (Filed With SEC on November 12, 2020)

Securities Purchase Agreement, by and between the Company and Astellas, dated October 21, 2022 (Filed With SEC on October 31, 2022)

Underwriting Agreement by and between Taysha Gene Therapies, Inc. and Goldman Sachs & Co. LLC, dated October 26, 2022 (Filed With SEC on October 27, 2022)

Loan and Security Agreement, dated August 12, 2021, by and among the Company, the lenders party thereto from time to time and Silicon Valley Bank, as administrative agent and... (Filed With SEC on August 16, 2021)

Lease Agreement, dated January 11, 2021, by and between Pegasus Place, LLC and the Company (Filed With SEC on August 16, 2021)

Amended and Restated Offer Letter, effective as of September 24, 2020, by and between the Company and Suyash Prasad (Filed With SEC on March 3, 2021)

Amended and Restated Offer Letter, effective as of September 24, 2020, by and between the Company and Kamran Alam (Filed With SEC on March 3, 2021)

Description of the Companys Common Stock (Filed With SEC on March 3, 2021)

Form of Underwriting Agreement (Filed With SEC on September 18, 2020)

Form of Amended and Restated Offer Letter, to be entered into by and between the Registrant and the Registrants Executive Officers (Filed With SEC on September 17, 2020)

Change in Control Severance Plan and Form of Participation Agreement (Filed With SEC on September 17, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on September 17, 2020)

Form of Indemnification Agreement with Executive Officers and Directors (Filed With SEC on September 17, 2020)

2020 Employee Stock Purchase Plan (Filed With SEC on September 17, 2020)

2020 Stock Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (Filed With SEC on September 17, 2020)

2020 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice, Early Exercise Notice and Restricted Stock Award Notice (as amended) (Filed With SEC on September 17, 2020)

Form of Underwriting Agreement (Filed With SEC on September 17, 2020)

Research, Collaboration & License Agreement, by and between the Registrant and The Board of Regents of the University of Texas System on behalf of The University of Texas... (Filed With SEC on September 2, 2020)

Executive Employment Agreement, by and between the Registrant and RA Session II, dated as of April 1, 2020 (Filed With SEC on September 2, 2020)

2020 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice, Early Exercise Notice and Restricted Stock Award Notice (Filed With SEC on September 2, 2020)

License Agreement, by and between the Registrant and Abeona Therapeutics Inc., dated as of August 14, 2020 (Filed With SEC on September 2, 2020)

License Agreement, by and between the Registrant and Queens University at Kingston, dated as of February 21, 2020 (Filed With SEC on September 2, 2020)

Amendment to Research, Collaboration & License Agreement, by and between the Registrant and The Board of Regents of the University of Texas System on behalf of The University of... (Filed With SEC on September 2, 2020)

Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated July 2, 2020 (Filed With SEC on September 2, 2020)

Taysha Gene Therapies, Inc. (29)